These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30374285)

  • 1. EEG Microstates Change in Response to Increase in Dopaminergic Stimulation in Typical Parkinson's Disease Patients.
    Serrano JI; Del Castillo MD; Cortés V; Mendes N; Arroyo A; Andreo J; Rocon E; Del Valle M; Herreros J; Romero JP
    Front Neurosci; 2018; 12():714. PubMed ID: 30374285
    [No Abstract]   [Full Text] [Related]  

  • 2. Are the EEG microstates correlated with motor and non-motor parameters in patients with Parkinson's disease?
    Costa TDC; Machado CBDS; Lemos Segundo RP; Silva JPDS; Silva ACT; Andrade RS; Rosa MRD; Smaili SM; Morya E; Costa-Ribeiro A; Lindquist ARR; Andrade SM; Machado DGDS
    Neurophysiol Clin; 2023 Feb; 53(1):102839. PubMed ID: 36716585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia.
    Chung JW; Burciu RG; Ofori E; Coombes SA; Christou EA; Okun MS; Hess CW; Vaillancourt DE
    Neuroimage Clin; 2018; 19():559-571. PubMed ID: 29984164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of levodopa and subthalamic stimulation on emotional conflict in Parkinson's disease.
    Martínez-Fernández R; Kibleur A; Chabardès S; Fraix V; Castrioto A; Lhommée E; Moro E; Lescoules L; Pelissier P; David O; Krack P
    Hum Brain Mapp; 2018 Dec; 39(12):5014-5027. PubMed ID: 30259598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dopaminergic treatment on functional cortico-cortical connectivity in Parkinson's disease.
    Zittel S; Heinbokel C; van der Vegt JP; Niessen E; Buhmann C; Gerloff C; Siebner HR; Münchau A; Bäumer T
    Exp Brain Res; 2015 Jan; 233(1):329-37. PubMed ID: 25300961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Role of Repetitive Transcranial Magnetic Stimulation in Alzheimer's and Parkinson's Disease: Electroencephalography Microstate Correlates.
    Hanoglu L; Toplutas E; Saricaoglu M; Velioglu HA; Yildiz S; Yulug B
    Front Neurosci; 2022; 16():798558. PubMed ID: 35250446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency-Specific Effects of Galvanic Vestibular Stimulation on Response-Time Performance in Parkinson's Disease.
    Lee S; Smith PF; Lee WH; McKeown MJ
    Front Neurol; 2021; 12():758122. PubMed ID: 34795633
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of deep brain stimulation in Parkinson's disease reflected in EEG microstates.
    Lamoš M; Bočková M; Goldemundová S; Baláž M; Chrastina J; Rektor I
    NPJ Parkinsons Dis; 2023 Apr; 9(1):63. PubMed ID: 37069159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of levodopa on electroencephalographic biomarkers of the parkinsonian state.
    Miller AM; Miocinovic S; Swann NC; Rajagopalan SS; Darevsky DM; Gilron R; de Hemptinne C; Ostrem JL; Starr PA
    J Neurophysiol; 2019 Jul; 122(1):290-299. PubMed ID: 31066605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic Medication Modulates Learning from Feedback and Error-Related Negativity in Parkinson's Disease: A Pilot Study.
    Volpato C; Schiff S; Facchini S; Silvoni S; Cavinato M; Piccione F; Antonini A; Birbaumer N
    Front Behav Neurosci; 2016; 10():205. PubMed ID: 27822182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age at Parkinson's disease onset modulates the effect of levodopa on response inhibition: Support for the dopamine overdose hypothesis from the antisaccade task.
    Waldthaler J; Stock L; Krüger-Zechlin C; Timmermann L
    Neuropsychologia; 2021 Dec; 163():108082. PubMed ID: 34728241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
    Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
    Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation.
    Moro E; Esselink RJ; Benabid AL; Pollak P
    Brain; 2002 Nov; 125(Pt 11):2408-17. PubMed ID: 12390968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease.
    Kolmančič K; Zupančič NK; Trošt M; Flisar D; Kramberger MG; Pirtošek Z; Kojović M
    Mov Disord; 2022 Jul; 37(7):1465-1473. PubMed ID: 35436354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa imparts a normalizing effect on default-mode network connectivity in non-demented Parkinson's disease.
    Zhong J; Guan X; Zhong X; Cao F; Gu Q; Guo T; Zhou C; Zeng Q; Wang J; Gao T; Zhang M
    Neurosci Lett; 2019 Jul; 705():159-166. PubMed ID: 31026534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The default mode network integrity in patients with Parkinson's disease is levodopa equivalent dose-dependent.
    Krajcovicova L; Mikl M; Marecek R; Rektorova I
    J Neural Transm (Vienna); 2012 Apr; 119(4):443-54. PubMed ID: 22002597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative EEG reflects non-dopaminergic disease severity in Parkinson's disease.
    Geraedts VJ; Marinus J; Gouw AA; Mosch A; Stam CJ; van Hilten JJ; Contarino MF; Tannemaat MR
    Clin Neurophysiol; 2018 Aug; 129(8):1748-1755. PubMed ID: 29887401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term effect of dopaminergic medication on speech in early-stage Parkinson's disease.
    Tykalova T; Novotny M; Ruzicka E; Dusek P; Rusz J
    NPJ Parkinsons Dis; 2022 Mar; 8(1):22. PubMed ID: 35256614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.